XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Segment Information
 6 Months Ended
Oct. 31, 2014
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
Note 9. Segment Information
 
The Company operates in two reportable segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual financial statements for the year ended April 30, 2014, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by reportable segment (in thousands):
 
 
 
 
Personalized Oncology Solutions
 
Translational Oncology Solutions
 
 
 
 
 
 
 
Three Months Ended October 31, 2014
 
(POS)
 
(TOS)
 
Unallocated Corporate Overhead
 
Consolidated
 
Net revenue
 
$
452
 
$
1,430
 
$
-
 
$
1,882
 
Direct cost of services
 
 
(745)
 
 
(943)
 
 
-
 
 
(1,688)
 
Sales and marketing costs
 
 
(423)
 
 
(611)
 
 
-
 
 
(1,034)
 
Other operating expenses
 
 
-
 
 
(1,142)
 
 
(864)
 
 
(2,006)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(820)
 
 
(820)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(716)
 
$
(1,266)
 
$
(1,684)
 
$
(3,666)
 
 
Three Months Ended October 31, 2013
 
Personalized Oncology Solutions
(POS)
 
Translational Oncology Solutions 
(TOS)
 
Unallocated Corporate Overhead
 
Consolidated
 
Net revenue
 
$
623
 
$
1,760
 
$
-
 
$
2,383
 
Direct cost of services
 
 
(726)
 
 
(696)
 
 
-
 
 
(1,422)
 
Sales and marketing costs
 
 
(423)
 
 
(213)
 
 
-
 
 
(636)
 
Other operating expenses
 
 
-
 
 
(673)
 
 
(877)
 
 
(1,550)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(476)
 
 
(476)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(526)
 
$
178
 
$
(1,353)
 
$
(1,701)
 
 
Six Months Ended October 31, 2014
 
Personalized Oncology Solutions
(POS)
 
Translational Oncology Solutions
(TOS)
 
Unallocated Corporate Overhead
 
Consolidated
 
Net revenue
 
$
792
 
$
3,001
 
$
-
 
$
3,793
 
Direct cost of services
 
 
(1,498)
 
 
(1,905)
 
 
-
 
 
(3,403)
 
Sales and marketing costs
 
 
(877)
 
 
(1,036)
 
 
-
 
 
(1,913)
 
Other operating expenses
 
 
-
 
 
(2,460)
 
 
(1,777)
 
 
(4,237)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(1,627)
 
 
(1,627)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(1,583)
 
$
(2,400)
 
$
(3,404)
 
$
(7,387)
 
 
Six Months Ended October 31, 2013
 
Personalized Oncology Solutions 
(POS)
 
Translational Oncology Solutions 
(TOS)
 
Unallocated Corporate Overhead
 
Consolidated
 
Net revenue
 
$
1,245
 
$
4,158
 
$
-
 
$
5,403
 
Direct cost of services
 
 
(1,470)
 
 
(1,566)
 
 
-
 
 
(3,036)
 
Sales and marketing costs
 
 
(754)
 
 
(460)
 
 
-
 
 
(1,214)
 
Other operating expenses
 
 
-
 
 
(1,063)
 
 
(1,534)
 
 
(2,597)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(1,028)
 
 
(1,028)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(979)
 
$
1,069
 
$
(2,562)
 
$
(2,472)
 
  
(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
 
All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.